Trials / Completed
CompletedNCT05759962
Phase 1 Study of LQT-1213 in Healthy Adults
A Phase 1, Randomized, Double-blinded, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluated the Safety, Tolerability, Pharmacokinetics, Food Effect, and Pharmacodynamics of LQT-1213 in Healthy Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Thryv Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This is a single-center, randomized, double-blind, placebo-controlled study to be conducted in 2 parts: single ascending dose (SAD) incorporating a food effect arm and multiple ascending dose (MAD). Potential participants for each part will undergo screening procedures within 28 days of enrollment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LQT-1213 | LQT-1213 is a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor |
| OTHER | Placebo | Matching Placebo |
Timeline
- Start date
- 2022-09-14
- Primary completion
- 2023-03-05
- Completion
- 2023-03-05
- First posted
- 2023-03-08
- Last updated
- 2023-09-26
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05759962. Inclusion in this directory is not an endorsement.